
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc has demonstrated promising results in its Phase 2b trial for OST-HER2, achieving a two-year overall survival rate of 75% in treated patients, significantly higher than the historical control rate of 40%. The company's upcoming biomarker correlation dataset, expected in November 2025, may strengthen its position for regulatory approval, especially given the supportive indications from major regulatory agencies like the UKMHRA and FDA regarding the use of historical control data. With a solid safety profile and the potential for conditional approval based on overall survival combined with biomarker data, OS Therapies appears well-positioned to advance its innovative treatments for osteosarcoma and other solid tumors.
Bears say
OS Therapies Inc faces significant financial challenges as it operates in a clinical stage environment with no current revenue from product sales, which raises concerns about the sustainability of its operations without additional funding. The company has reported increasing expenses related to research and development, indicating a high burn rate that could dilute shareholder value if further capital is needed to advance its pipeline. Furthermore, the competitive landscape for oncology treatments presents additional risks, as the company may struggle to differentiate its offerings or gain market acceptance amidst established players with more robust financial backing.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares